Inquérito sorológico sôbre leptospiroses realizado no Vale do Cariri, Estado do Ceará, pela III Bandeira Científica do Centro Acadêmico Oswaldo Cruz da Faculdade de Medicina da Universidade de São Paulo

Agglutination-tests for leptospirosis were performed in 376 sera. The following sero-types of Leptospira were used: L. icterohemorrhagiae, L. canicola, L. grippo-typhosa, L. pomona, L. bataviae, L. australis B, L. sejroe, L. pyrogenes and L. suis. Six sera (1.59%) were positive for L. icterohemorrhagiae. From the whole group two people were born in this region, what makes possible the conclusion that the disease exists in the region.Com o propósito de estudar o problema das leptospiroses no Vale do Cariri, Ceará, foram examinados 376 soros colhidos entre moradores da região. Foram feitas provas de sôro-aglutinação usando-se os seguintes sôro-tipos de Leptospira: L. icterohemorrhagiae, L. canícola, L. grippo-typhosa, L. pomona, L. bataviae, L. australis B, L. sejroe, L. pyrogenes e L. suis. Seis soros reagiram positivamente frente à L. icterohemorrhagiae, o que dá percentual de 1,59%. Dois dos indivíduos haviam nascido e vivido no Vale, donde foi possível concluir que a leptospirose existe, autóctone, na região

Colangite Oriental: relato de caso e revisão bibliográfica

Colangite oriental é uma doença rara em não asiáticos. Tem sido relacionada com infecção por Clonorchis sinensis e Ascaris lumbricóides. Neste artigo, é relatado o caso de uma paciente do sexo feminino, 37 anos, com o diagnóstico de colangite piogênica recorrente, destacando a dificuldade e demora do diagnóstico

The Schenberg spherical gravitational wave detector: the first commissioning runs

Here we present a status report of the first spherical antenna project equipped with a set of parametric transducers for gravitational detection. The Mario Schenberg, as it is called, started its commissioning phase at the Physics Institute of the University of Sao Paulo, in September 2006, under the full support of FAPESP. We have been testing the three preliminary parametric transducer systems in order to prepare the detector for the next cryogenic run, when it will be calibrated. We are also developing sapphire oscillators that will replace the current ones thereby providing better performance. We also plan to install eight transducers in the near future, six of which are of the two-mode type and arranged according to the truncated icosahedron configuration. The other two, which will be placed close to the sphere equator, will be mechanically non-resonant. In doing so, we want to verify that if the Schenberg antenna can become a wideband gravitational wave detector through the use of an ultra-high sensitivity non-resonant transducer constructed using the recent achievements of nanotechnology

Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

BACKGROUND The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. METHODS We randomly assigned 8256 patients (inpatients and outpatients) with symptomatic chronic heart failure and an ejection fraction of 35% or less to receive omecamtiv mecarbil (using pharmacokinetic-guided doses of 25 mg, 37.5 mg, or 50 mg twice daily) or placebo, in addition to standard heart-failure therapy. The primary outcome was a composite of a first heart-failure event (hospitalization or urgent visit for heart failure) or death from cardiovascular causes. RESULTS During a median of 21.8 months, a primary-outcome event occurred in 1523 of 4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.86 to 0.99; P = 0.03). A total of 808 patients (19.6%) and 798 patients (19.4%), respectively, died from cardiovascular causes (hazard ratio, 1.01; 95% CI, 0.92 to 1.11). There was no significant difference between groups in the change from baseline on the Kansas City Cardiomyopathy Questionnaire total symptom score. At week 24, the change from baseline for the median N-terminal pro-B-type natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in the placebo group; the median cardiac troponin I level was 4 ng per liter higher. The frequency of cardiac ischemic and ventricular arrhythmia events was similar in the two groups. CONCLUSIONS Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Amgen and others; GALACTIC-HF ClinicalTrials.gov number, NCT02929329; EudraCT number, 2016 -002299-28.)